健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

603707 健友股份

交易中 08-14 11:24:41

{"stockData":{"symbol":"603707","market":"SH","secType":"STK","nameCN":"健友股份","latestPrice":8.13,"timestamp":1786677881000,"preClose":8.21,"halted":0,"volume":5825900,"delay":0,"changeRate":-0.0097,"floatShares":1616000000,"shares":1616000000,"eps":0.3626,"marketStatus":"交易中","change":-0.08,"latestTime":"08-14 11:24:41","open":8.19,"high":8.27,"low":8.1,"amount":47664500,"amplitude":0.0207,"askPrice":8.13,"askSize":200,"bidPrice":8.12,"bidSize":196,"shortable":0,"etf":0,"ttmEps":0.3626,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1786678200000},"marketStatusCode":2,"adr":0,"adjPreClose":8.21,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":9.03,"lowLimit":7.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1615651020,"isCdr":false,"pbRate":1.91,"roa":"--","peRate":22.421401,"roe":"1.28%","epsLYR":0.36,"committee":0.569449,"marketValue":13135000000,"turnoverRate":0.0036,"status":1,"floatMarketCap":13135000000},"requestUrl":"/m/hq/s/603707/","defaultTab":"news","newsList":[{"id":"2658981939","title":"健友股份董秘黄锡伟荣获第十二届金麒麟·金牌董秘荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2658981939","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658981939?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:51","pubTimestamp":1786351860,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级专题：专题：第十二届金麒麟·金牌董秘及优秀证代荣誉榜单揭晓！8月10日，新浪财经第十二届金麒麟金牌董秘榜单正式揭晓。健友股份董事会秘书黄锡伟凭借扎实的合规治理能力、成熟的投资者关系运营、长期稳健的资本价值传递表现，荣耀加冕第十二届金麒麟金牌董秘。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-08-10/doc-inimvnpm8143785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658809608","title":"股市必读：健友股份（603707）8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658809608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658809608?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:14","pubTimestamp":1786299252,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，健友股份报收于8.1元，上涨2.02%，换手率0.73%，成交量11.87万手，成交额9496.83万元。董秘最新回复投资者： 创新药板块最近有些起色了，公司之前说的几款创新药产品进展怎么样了？未来，公司将持续推进创新管线研发转化，后续项目有重大进展，公司将及时履行信息披露义务，感谢您的关注。当日关注点交易信息汇总：8月7日主力资金净流出363.16万元，占总成交额3.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616364","title":"健友股份：来法莫林注射剂已在美国启动商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616364?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:39","pubTimestamp":1786091948,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份08月07日在投资者关系平台上答复投资者关心的问题。未来，公司将持续推进创新管线研发转化，后续项目有重大进展，公司将及时履行信息披露义务，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656134383","title":"股市必读：健友股份（603707）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656134383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656134383?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:15","pubTimestamp":1785694513,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，健友股份报收于8.09元，下跌0.61%，换手率0.62%，成交量10.05万手，成交额8138.13万元。董秘最新回复投资者： 看到公司门冬胰岛素从FDA获批了，后期在美国的销售是主要通过Meitheal公司开展吗？当日关注点交易信息汇总：7月31日主力资金净流出416.54万元，占总成交额5.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654906570","title":"健友股份(603707.SH)：门冬胰岛素注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654906570","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654906570?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:36","pubTimestamp":1785137802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司全资子公司Emerge Bioscience Pte.Ltd.(以下简称“Emerge”)于近日收到美国食品药品监督管理局(以下简称“美国FDA”)签发的门冬胰岛素注射液的BLA批准信(BLA号：761497/Original1)。本次门冬胰岛素注射液获得美国FDA批准，将进一步提升公司产品的国际影响力，丰富公司国际市场产品线，提高公司国际市场竞争力。若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LABU","BK4588","BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654064285","title":"股市必读：健友股份（603707）7月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654064285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654064285?lang=zh_cn&edition=full","pubTime":"2026-07-27 02:26","pubTimestamp":1785090373,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，健友股份报收于7.55元，下跌4.07%，换手率0.63%，成交量10.22万手，成交额7845.77万元。董秘最新回复投资者： 公司生物类似药和创新药的布局怎么样了？公司将持续加大研发投入，推动生物类似药与创新药业务成为继肝素、无菌注射剂之后新的增长引擎，具体研发进展及商业化节奏以公司定期报告披露为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083706","title":"健友股份：2025年是公司生物类似药商业化的重要节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653083706?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:54","pubTimestamp":1784886861,"startTime":"0","endTime":"0","summary":"2025年是公司生物类似药商业化的重要节点：中国首个阿达木单抗生物类似物获得美国FDA批准上市，利拉鲁肽生物类似药也于2025年4月获批，获批后实现较快的销售放量。公司将持续加大研发投入，推动生物类似药与创新药业务成为继肝素、无菌注射剂之后新的增长引擎，具体研发进展及商业化节奏以公司定期报告披露为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400031495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","603707","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653536737","title":"健友股份：FDA对中国厂区现场核查标准持续收紧","url":"https://stock-news.laohu8.com/highlight/detail?id=2653536737","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653536737?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:42","pubTimestamp":1784709743,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份(603707)07月22日在投资者关系平台上答复投资者关心的问题。投资者提问：看新闻最近有好几家药企都收到了FDA监管文件，健友目前有没有类似风险？健友股份回复：尊敬的投资者您好，公司高度关注同业出海企业的监管动态。整体看，FDA对中国厂区的现场核查标准持续收紧，生产质量体系的稳定性已成为出海药企能否顺利获批的核心变量。公司深耕肝素及无菌注射剂领域二十余年，目前拥有12条通过美国FDA审核的注射剂生产线，各产线运行稳定，公司将持续保持对质量体系的高标准投入。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0046","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652426010","title":"股市必读：健友股份（603707）7月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2652426010","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652426010?lang=zh_cn&edition=full","pubTime":"2026-07-17 01:40","pubTimestamp":1784223620,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，健友股份报收于8.28元，上涨3.63%，换手率1.59%，成交量25.64万手，成交额2.09亿元。董秘最新回复投资者： 想问下公司截至提问之日的股东人数。董秘： 投资者您好，相关疑问回复如下：1、公司及管理层严格遵守证券监管法规，不存在配合资金控盘、打压股价等违法违规行为，二级市场股价受宏观、行业、资金情绪等多重因素影响，公司无法左右股价走势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700000897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196443","title":"健友股份：公司及管理层严格遵守证券监管法规","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651196443?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:06","pubTimestamp":1784196382,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月16日在投资者关系平台上答复投资者关心的问题。健友股份回复：投资者您好，相关疑问回复如下：1、公司及管理层严格遵守证券监管法规，不存在配合资金控盘、打压股价等违法违规行为，二级市场股价受宏观、行业、资金情绪等多重因素影响，公司无法左右股价走势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600031900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0046","603707","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651443160","title":"健友股份：研发注册生产及全球商业化全链条布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651443160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651443160?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:06","pubTimestamp":1784196381,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月16日在投资者关系平台上答复投资者关心的问题。而健友的定位是研发、注册、生产以及全球商业化全链条布局，也是国内少数自建美国完整营销团队、新加坡区域运营中心、高端无菌产能的企业。公司的业务布局不只是 “产品出海”，而是输出整套合规制造、国际申报、本地化销售能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600031898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651448247","title":"健友股份：不存在隐瞒重大利空情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2651448247","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651448247?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:51","pubTimestamp":1784195477,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月16日在投资者关系平台上答复投资者关心的问题。当前股价下跌主要受全市场医药板块情绪、短期利润阶段性承压影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600029405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651165704","title":"股市必读：健友股份（603707）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651165704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651165704?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:41","pubTimestamp":1783878068,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，健友股份报收于7.49元，上涨3.45%，换手率0.94%，成交量15.22万手，成交额1.13亿元。董秘最新回复投资者： 现在公司股价持续下行，是否存在市场对公司价值逻辑的认知偏差？目前公司与通化东宝的战略合作核心聚焦于美国市场。公司将持续跟踪全球各法规市场的政策与行业机遇，稳步推进生物药的全球化布局，后续若有重大合作进展或注册获批事项，公司将及时披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650502154","title":"每周股票复盘：健友股份（603707）获丙泊酚注射液注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2650502154","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650502154?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:16","pubTimestamp":1783793770,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，健友股份报收于7.49元，较上周的7.64元下跌1.96%。本周，健友股份7月6日盘中最高价报7.74元。本周关注点公司公告汇总：健友股份获丙泊酚乳状注射液药品注册批件，视同通过一致性评价。丙泊酚乳状注射液适用于全身麻醉诱导与维持、重症监护成年患者镇静及临床操作清醒镇静。此次获批标志着公司具备该产品境内上市销售资格，有助于完善产品管线布局，提升市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650913189","title":"健友股份：小分子注射剂每年获批计十余款","url":"https://stock-news.laohu8.com/highlight/detail?id=2650913189","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650913189?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:45","pubTimestamp":1783676721,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月10日在投资者关系平台上答复投资者关心的问题。介绍一下未来2-3年申报获批规划，以及现有产能能否匹配后续需求？健友股份回复：尊敬的投资者您好，公司小分子注射剂每年获批计十余款，聚焦麻醉、抗肿瘤等高壁垒赛道，现有12条FDA无菌产线可支撑近三年放量。生物药方面，利拉鲁肽FDA获批后持续海外销售；阿达木单抗已在美上市；在研单抗XTMAB正推进三期临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000032240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0046","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650186077","title":"健友股份：与通化东宝战略合作核心聚焦于美国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2650186077","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650186077?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:33","pubTimestamp":1783676003,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月10日在投资者关系平台上答复投资者关心的问题。年报显示，门冬胰岛素正在向欧洲和美国获批中，跟通化东宝的合作未来也包含欧洲市场吗？目前公司与通化东宝的战略合作核心聚焦于美国市场。公司已获得包括门冬胰岛素等相关产品在美国的独家商业化权益，合作协议范围尚未包含欧洲市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","600867","BK0188","BK0239","BK0196","603707","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650078186","title":"健友股份：当前股价下跌主要受全市场医药板块情绪、短期利润阶段性承压影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2650078186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650078186?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:33","pubTimestamp":1783675998,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月10日在投资者关系平台上答复投资者关心的问题。目前公司海外制剂与生物药业务增长动能充足，核心研发管线稳步推进，基本面转型逻辑持续兑现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","BK0186","BK1161","BK0239","09939","BK1574","603707","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649628854","title":"健友股份（603707）披露子公司获美国FDA醋酸去氨加压素注射液生产场地转移注册批件，7月6日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649628854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649628854?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:43","pubTimestamp":1783331038,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，健友股份报收于7.61元，较前一交易日下跌0.39%，最新总市值为122.95亿元。近日，南京健友生化制药股份有限公司子公司Meitheal Pharmaceuticals, Inc.收到美国FDA通知，其申报的醋酸去氨加压素注射液生产场地转移至健进制药有限公司的申请已获批准。此次获批表明公司无菌注射剂生产线及质量体系符合美国cGMP标准，有助于丰富北美医疗机构注射剂产品线，完善海外供应链体系，中长期有望对公司经营业绩产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600025190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649264219","title":"健友股份(603707.SH)获得丙泊酚乳状注射液药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2649264219","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649264219?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:37","pubTimestamp":1783327022,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司于近日收到国家药品监督管理局(简称“NMPA”)签发的丙泊酚乳状注射液20ml：200mg的药品注册证书(药品批准文号为国药准字H20264830)。适应症：本品为短效静脉麻醉药，临床用于全身麻醉诱导与维持;重症监护成年机械通气患者镇静;外科手术、临床诊断操作的清醒镇静。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健友股份(603707.SH)获得丙泊酚乳状注射液药品注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603707","BK0186","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694296","title":"每周股票复盘：健友股份（603707）子公司获FDA批件完善海外供应链","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694296","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649694296?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:48","pubTimestamp":1783190891,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，健友股份报收于7.64元，较上周的6.84元上涨11.7%。本周，健友股份7月3日盘中最高价报7.72元。此次获批表明公司无菌注射剂生产线及质量体系符合美国cGMP标准，有助于丰富公司北美医疗机构注射剂产品线，进一步完善海外供应链体系，中长期有望对公司经营业绩产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786677895954,"stockEarnings":[{"period":"1week","weight":0.034},{"period":"1month","weight":0.0459},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.1541},{"period":"1year","weight":-0.2757},{"period":"ytd","weight":-0.0792}],"compareEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.0504},{"period":"6month","weight":-0.038},{"period":"1year","weight":0.0661},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京健友生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35693人(较上一季度减少6.31%)","perCapita":"45265股","listingDate":"2017-07-19","address":"江苏省南京市浦口区高新开发区MA010-1号地","registeredCapital":"161565万元","survey":"　　南京健友生化制药股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是标准肝素原料药、制剂、CDMO。截至报告期末，公司及子公司共拥有超过100项境外药品注册批件、超过30项中国药品注册批件。","listedPrice":7.21},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健友股份,603707,健友股份股票,健友股份股票老虎,健友股份股票老虎国际,健友股份行情,健友股份股票行情,健友股份股价,健友股份股市,健友股份股票价格,健友股份股票交易,健友股份股票购买,健友股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}